|
- FDA approves sotorasib with panitumumab for colorectal cancer
On January 15, 2025, the Food and Drug Administration approved sotorasib (Lumakras, Amgen Inc ) with panitumumab (Vectibix, Amgen Inc ) for adult patients with KRAS G12C-mutated metastatic
- Treatment for KRAS G12C-mutated metastatic CRC approved by FDA
The U S Food and Drug Administration has approved sotorasib in combination with panitumumab for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer
- FDA Approves First Colorectal Cancer Treatment that Targets . . .
The targeted therapy adagrasib received accelerated approved for colorectal cancer caused by a mutation called KRAS-G12C, when used in combination with the drug cetuximab MSK investigators have led much of the research that resulted in this combined drug approval
- FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH . . .
In June 2017, the FDA approved a refined indication for Vectibix for use in patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) mCRC, specifically as first-line therapy in combination with FOLFOX and as monotherapy following disease progression after prior treatment with
- FDA Approves Sotorasib Plus Panitumumab for KRAS G12C-Mutated . . .
The combination treatment specifically targets KRAS-mutated metastatic colorectal cancer (CRC) to improve progression-free survival The approval was based on results from CodeBreaK 300, a phase 3
- FDA Approves Sotorasib Plus Panitumumab for KRAS G12C–Mutated . . .
The FDA approved sotorasib plus panitumumab for adult select patients with KRAS G12C–mutated metastatic colorectal cancer
- FDA Approves Adagrasib With Cetuximab in KRAS G12C-Mutated CRC
The combination of adagrasib (Krazati) with cetuximab (Erbitux) is now an FDA-approved treatment option for patients with previously treated locally advanced or metastatic colorectal cancer (CRC) with a KRAS G12C mutation Adagrasib is a highly selective and potent oral small-molecule inhibitor of KRAS G12C
- FDA Approves KRAZATI® with ERBITUX® for KRAS G12C-Mutated . . .
SUMMARY: The FDA on June 21, 2024, granted accelerated approval to Adagrasib (KRAZATI®) plus Cetuximab (ERBITUX®) for adults with KRAS G12C-mutated locally advanced or metastatic Colorectal Cancer (CRC), as determined by an FDA-approved test, who have received prior treatment with Fluoropyrimidine, Oxaliplatin, and Irinotecan-based chemotherapy Colorectal cancer is the third most common
|
|
|